How InflaRx N.V. plans to challenge avacopan in ANCA-associated vasculitis with izicopan
InflaRx N.V. is expanding izicopan into renal inflammation and vasculitis markets. Discover what this means for complement inhibitor competition.
Pharma & Biotech
Pharma & Biotech
Why Sobi’s EMPAVELI approval in Canada may change the rare kidney disease treatment landscape
Health Canada clears EMPAVELI for C3G and IC-MPGN. Read what this changes for nephrology treatment, market access, and rare kidney disease care.
Pharma & Biotech
Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?
NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.